GlobeNewswire Inc | Nov 3, 2020 08:00AM EST

November 03, 2020

GAITHERSBURG, Md., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will release its third quarter 2020 financial results on Tuesday, November 10, 2020.

Altimmune management will host a conference call for investors beginning at 8:30 a.m. ET on Tuesday, November 10, 2020 to discuss the financial results and provide a business update.

Conference Call Details

Date: Tuesday, November 10thTime: 8:30 am Eastern TimeDomestic: 877-300-8521International: 412-317-6026Conference ID: 10149733Webcast: http://public.viavid.com/index.php?id=142319

About AltimmuneAltimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID), anthrax (NasoShield) and influenza (NasoVAX); an intranasal immune modulating therapeutic for COVID-19 (T-COVID); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell). For more information on Altimmune, please visit www.altimmune.com.

Investor Contacts: Will Brown Ashley R. RobinsonChief Financial Officer LifeSci Advisors, LLCPhone: 240-654-1450 617-430-7577wbrown@altimmune.com arr@lifesciadvisors.com Media Contacts: Warren Rizzi Sard Verbinnen & Co. Phone: 212-687-8080 altimmune-svc@sardverb.com